Spiro 1,3,4-thiadiazoline derivatives as ksp inhibitors

A compound or a pharmaceutically acceptable salt or isomer thereof, wherein said compound has a general structure according to Formula (IV):

• wherein R1, R2, R3, p, ring A, and ring B and the optional groups attached to ring B are each selected independently of each other and wherein:
• ring B is an unsubstituted or substituted aromatic said substituents on said aromatic ring or said heteroaromatic ring (when present) being independently selected from the group consisting of halogen;
• R1 is unsubstituted aryl or aryl substituted with one or more substituents, which can be the same or different, each substituent being independently selected from the group consisting of halogen;
• R2 is selected from the group consisting of —C(O)R7, —C(O)NR9R10, —C(O)NR9(OR10), —C(O)OR8, —N(R9)OR10, —N(R9)NHR10, —N(R9)N(alkyl)R10, and —N(R9)N(heteroalkyl)R10;
• p is 0, 1, or 2;
• and
• each R3 is independently selected from the group consisting of alkyl, heteroalkyl, alkenyl, heteroalkenyl, —CN, —NO2, —OR19, —OC(O)OR20, —NR21R22, —C(O)R24, —C(S)R24, —C(O)OR20, and —C(O)NR25R26,
• wherein each said alkyl, each said heteroalkyl, each said alkenyl, and each said heteroalkenyl, is unsubstituted or optionally independently substituted with one or more substituents, which can be the same or different, each substituent being independently selected from the group of oxo, halogen, —CN, —NO2, alkyl, heteroalkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, azido, —OR19, —OC(O)OR20, NR21R22, —NR23SO2R24, —NR23C(O)R20, —NR23C(O)R24, —SO2NR25R26, —C(O)R24, —C(O)OR20, —SR19, —S(O)R19, —SO2R19, —OC(O)R24, —C(O)NR26R26, —NR23C(N—CN)NR25R26 and —NR23C(O)NR25R26.

A compound, or a pharmaceutically acceptable salt or isomer thereof, selected from the group consisting of:

• Example No.
• Structure
• 101
• 201
• 202
• 203
• 204
• 205
• 206